The 200 SMA is .0061 the price is .0057, this company shouldn’t be relying on these incremental adjustments and tweaks it needs to make a splash in the market, sell something to a major company provide a service to a major company, become credible this is the opportunity moment

Why not tomorrow, charts are ready for a deal, the 200 SMA is .0009 and the price is .0008.

Wow very similar to Google, billions of advert impressions, 90 mill annual revenue guidance raised higher, very low float and a net profit? 3 handle? Could be 30.00 soon.

“8:31a ET 11/8/2022 - BusinessWire
Cenntro Facility in Herne, Germany Begins Assembly of Metro and TeeMak Models

Cenntro Electric Group Limited (NASDAQ: CENN), a leading EV technology company with advanced, market-validated electric commercial vehicles, today announced that its facility in Herne, Germany, acquired through its acquisition of Cenntro Automotive Europe, has completed its production transition and had begun assembly of two Cenntro models, the Metro and the TeeMak.

This latest expansion is one of several milestones that Cenntro has made in recent months. In addition to expansion of its manufacturing facilities, Cenntro has recently launched two new models, the Logistar 100 and the Logistar 260, and commenced deliveries of the Logistar 200 in Europe.

"We're very pleased to announce the full transition of the first two lines at the Herne facility," said Peter Wang, Cenntro Chairman and CEO. "The Herne facility will allow us to meet the growing market demands of our European customers."

The Herne facility is comprised of an assembly area and engineering center, along with several acres designated for product storage. While the Herne facility is initially set up to assemble the Metro and TeeMak, Cenntro anticipates adding assembly of vehicles from the Logistar line and the Antric One Cargo Bicycle in the near future.

"Assembling the Metro and the TeeMak at the Herne facility enables Cenntro to better align our vehicles with our customers' demands," continued Wang. "Through the addition of this strategic assembly location, Cenntro can remain at the forefront of industry by providing increased capacity and outstanding customer service for both current and prospective partners."”

Bid 1.57… up .13 cents 1.44 to 1.57 since NASA announcement on 6/15/22. NASA and the entire billionaire class should be ashamed of this shareprice as they frequently peddle the words “progress” and “science”. Looks like when it came down to it they left progress and science to itself as a valueless commodity to them. All can see in what occurred here what the financial leadership of the world truly values as important. While Cloud computing companies are at 200 a share at this moment and nobody even can explain what they do, which is little to nothing tangible.

Heading for 9th close below lower bollinger band on 6th month chart without a retest of the upper band. This means that if it ever reversed higher it can close above the upper band 9 times in a row without a reversal lower imo. Everything has to even out technically for any company making frequent deals, increasing revenue quarter over quarter and yoy, and communicating consistently.

95% discount from SP high exactly one year ago and in my opinion further along in company development, chart is favorable imo, news is due, revenues are occurring is their claim.

.16 cents of SP value increase in five months achieved:

“NASA, Dhruva, Teledyne, Exo-Space, SpaceX, Momentus, Parsons, an announcement of revenue greater than Q2, Exo-Space again, Vaya Space, Mission Space, Dawn Aerospace”

OS low… 18.94 million

Earnings 11/14

For what it’s worth the 100 SMA crossed below the 200 SMA on the 6 month chart and that did not result in a sell off which is bullish, again, the company has an opportunity to prove itself now that the smas are favorable.

“7:30a ET 11/9/2022 - Globe Newswire
Irwin Naturals Looks to Add Pacific Northwest Ketamine Clinic to Its National Footprint

Planned addition of Washington facility would mark 17th Prospective clinic signed to join fast-growing network for psychedelic mental healthcareGlobeNewswireNovember 09, 2022
LOS ANGELES, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company") has reached a binding, arm's length agreement to acquire the assets of Tri-Cities Infusion & Wellness Clinic, PLLC on November 5, 2022 which is located in Kennewick, Washington.


This will be the first facility in Washington for Irwin Naturals Emergence, a fast-growing national chain of psychedelic mental-health clinics. This will be the 17th facility the chain has signed on or acquired across eight different states.

Klee Irwin, CEO of Irwin Naturals said, "We believe this type of treatment has the capacity to change the way we care for mental health in this country. We've sought to move to the front of this market by moving fast while also being incredibly selective. Ben and Tyler have built a practice that epitomizes what we're looking for both in terms of top-notch care as well as sound business fundamentals."

Tyler Thornock and Ben Clark are the co-owners of the clinic, which opened in April 2019. They combine to offer more than 20 years of experience in the field. Both are certified registered nurses with special training for anesthesia.

The clinic offers ketamine infusion, which has been used to treat a variety of mood disorders. It also offers nutrient IV infusions, aesthetic procedures and regenerative treatments such as platelet-rich plasma (PRP) injections.

Ben Clark, CRNA, APRN, owner of Tri-Cities Wellness, said, "We noticed a void in our area when it came to ketamine treatment, and built our practice to bring these life-changing treatments to our community. Becoming part of Irwin Naturals Emergence gives us a chance to join something bigger that will create change on a truly national scale."

Irwin Naturals began in 1994, providing best-in-class nutraceutical products. Today, Irwin Naturals products are stocked on the shelves of more than 100,000 storefronts in North America and its brand name is recognized in 80 percent of U.S. homes.1

The Company moved into psychedelic mental healthcare earlier this year, announcing its plan to build a national chain of clinics under the umbrella of Irwin Naturals Emergence. It has vetted the more than 600 independent ketamine clinics currently operating in the United States, seeking to identify profitable clinics whose level of customer care meets the exacting standards embodied by the Irwin Naturals brand. The Company has sought to add those clinics that meet these criteria to Irwin Naturals Emergence, which is a wholly owned subsidiary of Irwin Naturals.

Irwin Naturals Emergence previously announced agreements with a total of 16 clinics located in seven different states. Last month, it announced an acquisition agreement with a clinic in Idaho.

Operating at a national scale will offer some increased efficiencies such as the ability to purchase services in bulk. Implementing economies of scale will also help drive down operating costs, a savings that can be passed on to customers by providing sliding-scale discounts and even pro bono treatment for those in need.

Klee Irwin, Irwin Naturals CEO, "We are a nationally known brand that our customers know and trust. This helps us not only provide security and assurance to our customers, essentially vouching for the quality of these treatments and services. It also gives us confidence as we apply our proven business approach to this exciting new area of care."

Transaction terms

The transaction is back-end loaded, aligning the sellers' interest with the Company and its shareholders. The total consideration is to be paid in stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. Further detail will be provided upon closing.”

They may want to withdraw all offerings and offer a product or service.

“IRVINE, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- ToughBuilt Industries, Inc. ("ToughBuilt") (NASDAQ:TBLT, TBLTW)))), announced today the Company's launch of 21 new SKUs into the global handsaws segment, beginning with a line of seven cutting tools featuring ToughBuilt's QuickSetâ?¢ Double-Edge Pull Saw, the first ever safe-folding pull saw. The new line will be available Q4 2022”

These saws will be useful to rebuild Florida.

“…and in fact no more shares will be sold in that offering as a Form 1-Z exit report was filed for it on October 6, 2022.

The Company is withdrawing the Offering Circular.”

https://www.sec.gov/Archives/edgar/data/772263/000139390522000439/nich_1aw.htm

This run for as long as it goes has much more to do with Hurricane Nich-ole than anything company related, so far, imo. There are investors whose strategy will be to buy every stock with the word Nick in it or any word derivative of that, and the company might be smart enough to take advantage of the artificially generated short term interest.

Might want to consider removing the F from the ticker as fees have increased from some brokers for foreign stock transactions

Last earnings was 75.12 yoy sales at the rate of sales for the quarter x 4, vs 78.65 OS,

“Second Quarter 2022 Financial Results

Total revenue was $18.8 million for the quarter ended June 30, 2022, compared with $31.0 million for the second quarter of 2021, driven by lower instrument and COVID-19 testing revenue. Base product and service revenue (excluding COVID-19 testing revenue) was $17.5 million, approximately 35% lower compared with $26.9 million for the second quarter of 2021.

GAAP net loss for the quarter ended June 30, 2022, was $63.5 million, compared with a GAAP net loss of $17.1 million for the second quarter of 2021. The year-over-year increase in GAAP net loss was driven by increases in fair value of the forward sale contract related to the Series B Preferred Stock and bridge loans aggregating $25.4 million, lower revenue, lower product and service margin, and higher operating expenses. Product line exits during the quarter negatively affected product and service gross profit and net loss by $4.7 million and $8.2 million, respectively.

Non-GAAP net loss, which excludes the fair value increases noted above, stock-based compensation, depreciation and amortization expenses, and interest expense, was $25.8 million for the quarter, compared with a non-GAAP net loss of $9.3 million for the second quarter of 2021.

Cash, cash equivalents and short-term investments as of June 30, 2022, were $211.2 million, compared with $30.0 million as of March 31, 2022.”

Reversal signal higher occurred today as the 6 month 100 SMA is finally pointing in 45 degree down angle and no longer sideways. The 50, 100, and 200 smas are all now supporting a move higher technically let’s see if that is what the market was waiting for.

Charts are primed and ready for lftoff

Top Bollinger band door opened today to the upside for an exponential growth trend opportunity

Still waiting for rate hikes to end for Bitcoin to find bottom

HammerPay, set to debut in Q4 2022, ”

https://hmmrgroup.com/media/f/hammerpay-announces-new-digital-fintech-platform-launch

Another hurricane is projected on US east coast, will boost tool and product demand for the quarter and could help increase margins.

This tech is a crucial tool to reducing every country’s dependence on oil and gas imports, “Advent always starts four Sundays before Christmas. This year, in 2022, Advent starts Sunday, November 27.”

Williams indicator one year chart anniversary of all time H is tomorrow, Macd 1 month has plenty room to run, and on Election Day in US…

Phun benefits from Twitter spam bot challenges musk is having, specifically by shining a light on tech that can solve the issue:

“As we approach the 2022 Midterm Elections and the 2024 Presidential Election, politicians and advocacy groups are looking for new ways to ensure that their target audiences stay informed, all while minimizing the noise created by large platforms like Twitter due to their ongoing spam bot and fake account challenges," said Alan S. Knitowski, President, CEO and Co-Founder of Phunware. "Our Smart Advocacy Solution delivers a digital center of gravity for any constituency, with tech integrations like these allowing our customers to have more control over their authenticity, displayed content and messaging instead of simply relying on algorithms or chance to determine who sees what and when they see it."

“9:14a ET 11/7/2022 - Benzinga
'Astra Space Give Launch System 2 Update' - SEC

EX-99.1 (sec.gov)

Since Astra's founding in 2016 we've been on a mission to Improve Life on Earth from Space® by delivering customer payloads to orbit through frequent and reliable dedicated launches as economically as possible.

Our goal with Launch System 1 was to achieve orbital capability as quickly as possible and demonstrate that we could mass-produce rockets. And we did, by launching incrementally more capable rockets â?? 1.0, 2.0, 3.0, 3.1, 3.2, and finally a series of Rocket 3.3 rockets that made Astra the fastest privately funded U.S. company to reach orbit.

Following the flight anomaly on our last launch, we listened to our customers, our team, and our stockholders and made the strategic decision to accelerate the introduction of a higher performance rocket and add additional testing that we believe will increase the reliability of future launches.

Launch System 2 is our answer to our existing launch customers, and an increasing number of satellite operators around the world, that need affordable and frequent dedicated orbital launch services to enable new space services. These launch services have the potential to unlock next generation communications services, critical national security and defense applications, and a wide range of Earth observation capabilities that will create a healthier planet.

We believe Launch System 2 will provide Astra's customers the launch services they need, whether that be constellation deployment, constellation management, or responsive missions. Dedicated small launches give satellite operators the ability to deploy their spacecraft directly to their operational orbits and allow them to start providing services and adding value sooner.

Our customers and the broader market were clear about wanting three things from Astra's new launch system: reliability, increased payload capacity, and an increased launch cadence. Launch System 2 has been specifically designed to address these needs.

While Launch System 1 made Astra the fastest privately funded U.S. company to reach orbit, the goal of Launch System 2 is to build a highly reliable system that we believe can scale to a weekly launch cadence.

Designed for Reliability & Scaled Manufacturing

While the new launch system builds on the heritage of Launch System 1, Launch System 2 is more than just upgraded hardware â?? it represents a cultural shift from our primary focus on schedule to a focus on reliability. This launch system is the result of a significant change in how Astra designs, builds, qualifies, and operates our launch system.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

200 SMA on 6 month chart is .0009, literally a ground floor opportunity in terms of chart resistance from smas, if a company steps in soon could see a major increase

“Revenue increased by 47.9% year-over-year to $2.74 million for the six months ended June 30, 2022 from $1.85 million for the same period last year.”

5.5 million annual revenue at that rate and 15.85 OS. Chart Gap at .64 cents. 9/7/22.

“7:30a ET 11/7/2022 - Globe Newswire
Irwin Naturals THC Products to be Available In Mississippi Dispensaries

Company announces licensing agreement with Mockingbird Cannabis in new medical marijuana marketGlobeNewswireNovember 07, 2022
LOS ANGELES, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company") announced today a licensing and supply agreement with Mockingbird Cannabis, LLC ("Mockingbird Cannabis") to produce and distribute Irwin Naturals THC products in Mississippi.

Klee Irwin, CEO of Irwin Naturals said, "For 28 years, we have safely cared for the health of our customers, and we look forward to being the trusted friend on the shelves of Mississippi dispensaries for medical marijuana. The state-of-the-art facility that Clint Patterson and his team have put together in Mississippi and their leading position in the market makes Mockingbird Cannabis the perfect partner as we seek to make Irwin Naturals THC products available in every state it is legal."

Clint Patterson, CEO Mockingbird Cannabis LLC said, "We're excited that Irwin Naturals chose us to produce and distribute this line of products. Irwin Naturals is a company that has made its name with first-in-class products, and we're excited to take this next step with them in Mississippi."

Irwin Naturals was founded in 1994,and has built itself into a brand recognized in 80 percent of American households1 with its best-in-class nutraceuticals, such as its famous "Power to Sleep." Irwin Naturals products are available in more than 100,000 stores in North America. Under this licensing agreement, Mockingbird Cannabis will augment Irwin Naturals products with THC and make them available to Mississippi dispensaries where they will be sold under the Irwin Naturals brand name.

Mockingbird Cannabis is the largest licensed medical marijuana cultivator currently operating in Mississippi. Its massive facility is located just outside Raymond, totaling more than 163,000 square feet with 16 grow rooms. It's expected to ultimately employ more than 200 people2. The property was formerly used by the state's Department of Revenue.

In 2020, Mississippi voters overwhelmingly approved an initiative to legalize marijuana for medical purposes. However, that initiative was struck down by the state's Supreme Court. The state legislature passed a bill earlier this year to legalize medical marijuana, and it was signed into law by the governor. As of last month, more than 100 dispensaries had been licensed by the state with the expectation that sales will begin by the end of the year.3 Mockingbird Cannabis is expected to be one of the first companies to have product that is ready to market.

Cannabis is now legal in the majority of states. However, because it is not legal at the federal level, products must be approved on a state-by-state basis. As a national brand, Irwin Naturals is leveraging its brand by reaching licensing agreements with cannabis manufacturers on a state-by-state basis.”

Air Force Illustrated Picture (Ilustrato Pictures), its pointing in the right direction for the SP imo, everything is connected:

https://taskandpurpose.com/news/air-force-kc-135-tanker-sky-penis-russia-syria/?amp

An algorithm can be built into Twitter to remove any reference to an OTC stock.

Today is the day, from 10/3: “Swifty Global CEO, James Gibbons, commented: "The company is now perfectly placed for its expansive growth plans, with a strong, highly experienced team and revolutionary certified software. Added to this, we are also excited about the upcoming submittal of our documentation in order to become fully reporting and to change our ticker and company name change from Dear Cashmere in the coming month."”

The entire process won’t remove the CE because it could cause wealth and inflation. I also think the FED is shorting the major markets. Notice how the article below only cites restrictions against FED officials and not the FED itself:

“February 18, 20223:04 PM ESTLast Updated 9 months ago
Federal Reserve adopts strict trading rules after ethics scandal

REUTERS/Joshua Roberts
Feb 18 (Reuters) - The Federal Reserve adopted a new set of investing and trading restrictions for its senior officials on Friday, barring a wider range of activities than was proposed last fall in the wake of an ethics scandal that shook confidence in the U.S. central bank's integrity.

They are meant "to ensure public confidence in the impartiality and integrity of the Committee’s work," the Fed said in a statement. The Fed's Federal Open Markets Committee is its policy-setting body.

Fed officials will be banned from purchasing sector funds, engaging in short sales, or buying securities on margin, as well as from holding cryptocurrencies, commodities or foreign currencies.”

Deals (in order of occurrence) Since June close of 1.44 : NASA, Dhruva, Teledyne, Exo-Space, SpaceX, Momentus, Parsons, an announcement of revenue greater than Q2, Exo-Space again, Vaya Space, Mission Space, Dawn Aerospace : current share price 1.64.

3 industry awards issued to company/employees in the above time-frame. Since the last close above the upper bollinger band on 7/21 it has closed below the lower bollinger band 8 times without a return to the upper bollinger band.

Trading at .1355 on a pre-split basis (closed at .22 pre-split)

Hoping for satellite deal with telcom industry, inflation opportunity here as consumers look to reduce costs imo

Macd awake first time since July, PR due in near term imo

“6:10a ET 10/21/2022 - Dow Jones
PLBY Group Is Maintained at Buy by Chardan Capital

Ratings actions from Benzinga: https://www.benzinga.com/stock/PLBY/ratings

(END) Dow Jones Newswires

October 21, 2022 06:10 ET (10:10 GMT)“

Usually a spike on the 5th or 6th day after a R/S to low float, see INPx and PIXY as recent examples.

“8:40a ET 10/13/2022 - Benzinga
Standard BioTools Announces Ascendas Genomics Receives NMPA Approval For Use Of Standard BioTools Microfluidics Technology To Advance The Development Of Molecular Diagnostics In China

Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose â?? Unleashing tools to accelerate breakthroughs in human healthâ?¢ â?? today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company's Biomarkâ?¢ family of systems and its Junoâ?¢ system in NMPA molecular diagnostics services, enabling an important advance for microfluidics technology in the country.

Ascendas Genomics is an innovative molecular diagnostics company with experience in developing high-performing assays for disease risk screening. Recent NMPA approval obtained by Ascendas Genomics enables further development of molecular diagnostics into the clinical market in China, expanding the application of microfluidics products and services.

This announcement builds upon a longstanding strategic partnership between Standard BioTools and Ascendas Genomics, by which Ascendas Genomics has developed and commercialized molecular diagnostic systems and assays in China using microfluidics technologies included in the Standard BioToolsâ?¢ Biomark real-time PCR and Juno systems.

"Ascendas recently started to approach several large CLIA labs in China, and they love Standard BioTools' microfluidics solution because of its automation, accuracy and simplicity," said Dr. Chengyong Yang, Chairman and CEO of Ascendas Genomics, referring to labs sanctioned under the Clinical Laboratory Improvement Amendments (CLIA). "Quantitative PCR is the gold standard for disease testing. High-throughput microfluidic qPCR technology creates a value different from traditional qPCR systems and could potentially become the gold standard for multiplex molecular diagnostic testing."

"Microfluidics technology plays a significant role in accelerating genomics analysis," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We are very pleased to continue our partnership with Ascendas Genomics to further expand our market position in China and better support testing and disease risk screening. We congratulate Ascendas Genomics on its recent approval and will work together to blend the scalable efficiencies of Biomark Xâ?¢ and Juno with Ascendas Genomics' expertise to advance precision medicine in China."

Used by researchers around the world to detect somatic and genomic variations from patient samples, microfluidics technology offers highly scalable and automated workflows for quantitative PCR and enables the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of molecular testing.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.“

“2:31p ET 10/11/2022 - Benzinga
Standard BioTools Announces Collaboration Agreement With Visikol To Offer Multiplex Imaging Mass Cytometry Services

https://investors.fluidigm.com/news-releases/news-release-details/standard-biotools-announces-collaboration-agreement-visikol

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.“

“8:30a ET 10/6/2022 - Globe Newswire
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needsGlobeNewswireOctober 06, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose -â?¯Unleashing tools to accelerate breakthroughs in human health(TM) - today announced the launch of the X9(TM) Real-Time PCR System, an innovative high-capacity genomics instrument offering superior efficiency.


X9 enables high data output with more than 9,000 individual nanoliter-volume reactions in a single run, ensuring cost-effective, comprehensive sample profiling with minimal operator contribution. Instead of using 96 plates worth of reagents, plastic and labor, X9 can reduce an experiment to a single integrated fluidic circuit (IFC) - a microfluidic chip. The X9 platform, powered by single-touchpoint operation, streamlines laboratory processes by integrating reaction setup into an automated workflow that generates up to 46,080 datapoints per 8-hour shift.

Agricultural genomics and clinical research labs require the flexibility to adapt to changing assay needs, so the ability to mix and match assays for quick and easy implementation with up to 96 targets is key. The X9 System integrates proven Standard BioTools(TM) proprietary microfluidics technology, which helps reduce experimental costs while accommodating relevant and popular applications and chemistries to meet the most demanding customer needs.

"We are committed to connecting the best solution to the needs of the customer, considering cost per sample or per run, throughput requirements, time to results and flexibility of content, among other factors," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Even with ongoing challenges of labor shortages and limited resources, labs are pressed to maintain the same level of output. X9 can help solve these issues by empowering these labs to work within their resources and do more with less.

"We are thrilled that this instrument is primed to support the researchers and core labs in agricultural genomics and clinical research communities, consistent with our sharpened commercial focus on high-value niche markets for specialized applications for which our platform is ideally suited. The system can support various real-time PCR studies, offering faster data output and better use of time."“